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Objectives The aim of this study was to compare clinical outcomes among unselected patients
stratiﬁed in categories of body mass index, who underwent percutaneous coronary intervention
(PCI) with either sirolimus-eluting or paclitaxel-eluting stents.
Background Overweight and obesity are often considered risk factors for cardiovascular events.
However, recent studies have associated obesity with better outcomes after PCI with bare-metal
stents. Data from routine clinical practice using drug-eluting stents (DES) focusing on this “obesity
paradox” are not available.
Methods We used data from DES.DE (German Drug-Eluting Stent) registry to compare in-hospital
and 1-year outcomes among unselected patients undergoing PCI with DES implantation. Primary
endpoints were the rate of major adverse cardiac and cerebrovascular events (MACCE) (deﬁned as
the composite of death, myocardial infarction, and stroke) and target vessel revascularization (TVR).
Results Between October 2005 and 2006, 1,436 normal weight, 2,839 overweight, and 1,531 obese
patients treated with DES were enrolled at 98 sites. Baseline clinical parameters were more severe in
overweight and obese patients; 1-year follow-up comparison between groups revealed similar rates
of all-cause death (3.3% vs. 2.4% vs. 2.4%; p  0.17), MACCE (7.1% vs. 5.6% vs. 5.5%; p  0.09), and
TVR in survivors (10.9% vs. 11.7% vs. 11.6%; p  0.56) in normal weight individuals compared with
overweight or obese patients. Such results persisted after risk-adjustment for heterogeneous base-
line characteristics of groups and were independent of the types of DES.
Conclusions DES.DE revealed no evidence of “obesity paradox” in a routine clinical practice us-
ing DES. (J Am Coll Cardiol Intv 2012;5:162–9) © 2012 by the American College of Cardiology
Foundation
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163Obesity is associated with significant morbidity and mor-
tality, and is increasingly prevalent and growing in western
societies, with two-thirds of the population being classified
as overweight or obese (1). Overweight and obese individ-
uals are at greater risk to develop coronary artery disease,
primarily because of obesity-related conditions, such as
diabetes mellitus, hypertension, and dyslipidemia (2). Al-
though the impact of obesity on clinical outcomes after
percutaneous coronary intervention (PCI) with bare-metal
stents (BMS) has been investigated by several studies, the issue
remains complex and controversial (3–7). Indeed, several studies
have reported better clinical outcomes in overweight and obese
subjects after PCI compared with normal and underweight
subjects, an interaction termed “obesity paradox” (3–7). Our
urrent analysis compares clinical outcomes after drug-eluting
tent (DES) between normal weight, overweight, and obese
atients in routine clinical practice followed 1 year in the large
rospective multicenter DES.DE (German Drug-Eluting Stent)
egistry.
ethods
Registry design. The DES.DE registry design has been pre-
iously published (8). Briefly, the prospective multicenter
erman DES.DE registry was initiated in October 2005 as an
bservational registry by Deutsche Gesellschaft für Kardiologie
DGK, German Cardiac Society), Bundesverband Niederge-
assener Kardiologen (BNK, German Society of Cardiologists
n Private Practice) and Arbeitsgemeinschaft Leitende Kardi-
logische Krankenhausärzte (ALKK, The Working Group of
eading Hospital Cardiologists) to analyze and evaluate the
herapeutic principle of DES under routine clinical practice
onditions in the context of the German Health System.
rug-eluting stents in DES.DE had to meet certain quality
riteria constituted and confirmed by the DES.DE steering
ommittee and were adopted from both European Society of
ardiology and American College of Cardiology/American
eart Association PCI guideline criteria for DES (9,10). In
hase I of the registry (October 2005 to October 2006), only
he 2 Food and Drug Administration–approved DES, Taxus,
nd Cypher, met all quality criteria of the registry. The
nterventional strategy, including choice of stent, use of intra-
ascular ultrasound, and the choice of periprocedural adjunctive
herapy, was at the discretion of the interventional operator
egardless of clinical setting.
Data collection and follow-up. Data were collected via In-
ernet platform by the Institut für Klinische Kardiologische
orschung (IKKF, Institute for Clinical Research) of the
erman Cardiac Society. The European Cardiology Audit
nd Registration Standard (CARDS) was adapted for both
atient and lesion data. Written informed consent for
rocessing of anonymous data at the Institut für Herzin-
arktforschung (IHF, Heart Centre Ludwigshafen) and
KKF was required; both clinical and angiographic charac- deristics were collected at IKKF. Quantitative coronary
ngiography was performed on digitally stored pre- and
ost-intervention angiograms using the program installed
n all catheterization laboratory–based workstations. Paper-
ased clinical follow-up and external telephone interviews
y an independent contract research organization were per-
ormed at 3, 6, 9, and 12 months after initial stent placement.
elevant events and randomly selected angiograms were for-
arded to 2 independent critical event committees for adjudica-
ion of stent thrombosis and validity (Online Appendix).
Deﬁnitions. According to the World Health Organization
nd National Heart, Lung, and
lood Institute, the patient popu-
ation was divided into normal
eight (body mass index [BMI]:
8.5 to 24.9 kg/m2), overweight
(BMI: 25 to 30 kg/m2), and obese
roups (30 kg/m2) (11,12). Pri-
mary objectives of the current survey
on patients in DES.DE were pre-
specified as the occurrence of target-
vessel revascularization (TVR) and
major adverse cardiac and cerebro-
vascular events (MACCE) (defined
as the composite of cardiac and
noncardiac death, myocardial in-
farction [MI], and stroke). Myocar-
dial infarction was either defined as
ST-segment elevation myocardial
infarction (STEMI) (ST-segment
elevation 1 mm in 2 or more
standard adjacent leads or 2 mm
n 2 or more contiguous precordial
eads, development of new left bun-
le branch block) or non–ST-
egment elevation myocardial in-
arction (NSTEMI) (pathological
ncrease of cardiac-specific enzymes
ith creatine kinase-myocardial
and 1.5 times the normal limit,
roponin T or I99th percentile of
he normal value). Acute coronary
yndrome (ACS) was defined as
TEMI, NSTEMI, or unstable angina according to the Euro-
ean Society of Cardiology or American College of Cardiology/
merican Heart Association guidelines (9,10). TVR includes
epeat procedures, either PCI or coronary artery bypass graft
CABG), in the target vessel. In a number of major adverse
ardiac events (MACE) definitions, different types of death
either cardiac or total death rate) and revascularization
arameters, such as TVR have been used. Because the use of
ifferent definitions of MACE can cause confusion when
omparing rates between trials, the steering committee
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BMI  body mass index
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
DES  drug-eluting stent(s)
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RR  relative risk
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularizationecided to use only MACCE as defined in the previous text.
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164Patients in the DES.DE registry were discouraged from
undergoing routine angiography for follow-up; therefore, all
reinterventions can be counted as clinically driven. Stent
thrombosis was classified according to the definition pro-
posed by the Academic Research Consortium (ARC) (13).
Bleeding complications were categorized according to the
GUSTO (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries)
classification; they were considered as major in case of severe
or moderate bleeding, whereas they were considered minor
in case of mild forms (14). Contrast-induced transient renal
failure requiring single dialysis during index hospitalization
was listed as an adverse event.
Statistical analysis. Statistical analysis was performed using
the SAS statistical package, version 9.1 (Cary, North
Carolina). Demographic characteristics, pre-existing risk fac-
tors, procedure-related variables, and 1-year outcomes were
summarized using mean and standard deviation for continuous
variables, and frequency and percentage for categorical vari-
Table 1. Baseline Demographics of Patients Receiving DES
BMI, kg/m2
p Trend
18.5–24.9
(n  1,436)
25–30
(n  2,839)
>30
(n  1,531)
Male 69.8 78.5 72.1 0.19
Age, yrs 66.1 11.0 65.5 10.1 63.7 10.3 0.0001
Diabetes 21.5 29.2 46.9 0.0001
Only dietary 17.3 14.1 12.5 0.05
Only oral hypoglycemic
agents
44.8 52.7 44.9 0.37
Insulin 35.9 29.6 39.7 0.05
Newly diagnosed 2.0 3.5 2.9 0.62
Hypercholesterinemia 75.9 81.0 83.5 0.0001
Renal insufﬁciency 11.9 12.4 13.5 0.19
History of heart failure 14.2 14.8 16.5 0.09
Hypertension 75.4 84.2 91.2 0.0001
Atrial ﬁbrillation 7.2 8.8 6.9 0.65
Smoking
Current 26.3 21.4 20.4 0.001
Previous 48.0 53.8 55.3 0.001
Family history of CAD 38.3 37.1 34.8 0.08
Previous myocardial
infarction
30.5 29.6 30.7 0.91
Previous PCI 41.9 45.8 45.1 0.09
Previous CABG 14.1 15.0 12.9 0.31
Previous stroke 4.3 4.5 4.3 0.94
Ejection fraction, %
50 70.9 68.1 68.7 0.25
41–50 17.6 19.9 18.2
31–40 8.2 8.2 9.7
30 3.2 3.9 3.4
Values are % or mean SD.
BMIbodymass index; CABG coronary arteries bypass graft; CAD coronary artery disease;sDES drug-eluting stent(s); PCI percutaneous coronary intervention.ables. Trends in baseline, procedural, and angiographic char-
acteristics and in-hospital and follow-up data were assessed
between normal weight, overweight, and obese patients by
Cochran-Armitage test, whereas continuous variables were
compared by 2-tailed Jonckheere-Terpstra test. Values of p 
0.05 were considered significant and were the result of 2-tailed
tests. One-year event-free survival rates for MACCE and
TVR were demonstrated by Kaplan-Meier curves and com-
pared by log-rank test. The effect of BMI (per increase of 5
kg/m2) on MACCE during the follow-up period was evalu-
ted by using multiple Cox regression to adjust for confound-
ng parameters. The effect on TVR within 12 months was
valuated using multiple logistic regression, excluding patients
ho had died during follow-up, in order to account for the
ifferential impact of risk factors between MACCE and TVR
8). The following variables were entered into a backward
Table 2. Descriptive Morphology of CAD in Patients Receiving DES
BMI, kg/m2
p Trend18.5–24.9 25–30> >30
Vessel disease
1 31.1 25.1 28.9 0.21
2 31.2 34.4 32.4
3 36.6 39.5 37.9
Target vessel
LAD 48.5 47.4 48.7 0.40
LCX 20.8 23.3 21.4
RCA 28.4 26.5 27.0
LMCA 2.4 2.9 3.0
Bypass graft 4.3 4.9 4.5
Lesion class AHA/ACC
A 12.7 12.9 11.9 0.28
B 61.6 59.5 59.7
C 25.7 27.6 28.4
TIMI ﬂow grade
0 10.8 13.0 12.0 0.31
1 8.4 8.6 10.9
2 23.4 20.7 22.1
3 57.3 57.7 54.9
Acute coronary syndrome
STEMI 11.8 10.2 10.3 0.95
NSTEMI 8.0 7.9 9.2 0.20
UAP 8.8 8.8 9.0 0.26
Chronic total occlusion 2.8 3.8 3.4 0.33
In-stent restenosis 15.9 15.5 15.5 0.79
Bifurcation 15.3 15.1 15.0 0.81
Values are %.
AHA/ACC American Heart Association/American College of Cardiology; LAD left anterior
descending coronary artery; LCX  left circumflex coronary artery; LMCA  left main coronary
artery; NSTEMI non–ST-segment elevation myocardial infarction; RCA right coronary artery;
TIMI Thrombolysis In Myocardial Infarction; STEMI ST-segment elevation myocardial infarc-
tion; UAP unstable angina pectoris; other abbreviations as in Table 1.election model for MACCE using a p value for removal of
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1650.05: female gender, age75 years, BMI elevation of 5 kg/m2,
current smoker, renal insufficiency, previous CABG, peripheral
arterial disease, STEMI, impaired left ventricular function
(ejection fraction 40%), heart failure. Similarly, in the mul-
ivariable model for TVR the following variables were entered:
revious PCI, STEMI, unstable angina, impaired left ventric-
lar function function (ejection fraction 40%), vessel diam-
ter (3 mm), and type C lesion.
esults
Baseline characteristics and procedural outcomes. Between
ctober 2005 and October 2006, 5,806 patients treated
ither with paclitaxel-eluting stents (PES) or sirolimus-
luting stents (SES) were enrolled at 98 sites in the
rospective DES.DE registry. Analysis was based on 2,884
atients (49.7%) who received a PES, on 2,264 (39.0%) who
ere treated with SES, and on 658 patients (11.4%) who
eceived both a PES and SES. Among these, 1,436 patients
24.7%) were classified as normal weight, 2,839 (48.9%) as
verweight, and 1,531 (26.4%) as obese. Mean age was 65.2 
0.4 years, with older patients in the normal weight category
s compared with overweight or obese groups (66.1  11.0
vs. 65.5  10.1 vs. 63.7  10.7; p  0.0001). Additionally,
both overweight and obese subsets suffered from more
Table 3. Procedural Characteristics of Patients Rece
18.5–24.9
Total lesions 1,597
Total implanted stents 1,888
Degree stenosis 87.2 10.6
Stent details, mm
Diameter 3.0 (2.5–3.0)
Length 18.0 (13.0–23.0)
Device usage
IVUS 0.5
Rotablation 0.3
Cutting balloon 0.5
Direct stenting 42.4
Residual stenosis 1.7 6.6
Post-procedural TIMI ﬂow grade 3 98.3
Lesion complication
Abrupt closure 0.4
Side-branch occlusion 0.3
Persistent ﬂow reduction 0.3
Clopidogrel loading dose
300 mg 34.5
600 mg 52.1
GP IIb/IIIa antagonist 15.9
Values are n, %, or mean SD.GP glycoprotein; IVUS intravascular ultrasound; other abbreviations assevere comorbidity index with diabetes mellitus (21.5% vs.
29.2% vs. 46.9%; p 0.0001). Conversely, smoking was less
frequent in the obese and overweight groups (26.3% vs.
20.4% vs. 21.4%; p  0.001) (Table 1).
Approximately one-third of all patients were admitted
with ACS with no difference in the distribution of STEMI,
NSTEMI, and unstable angina among subsets (Table 2);
baseline demographics and descriptive data, such as previous
CABG, previous PCI, and mild impairment of left ventric-
ular function were also similar (Table 1).
Overall, 7,701 stents were implanted in 6,479 lesions of
5,806 patients (1.32 stents/patient and 1.19 stents/lesion)
with a procedural success rate of 98.6%; stents were de-
ployed in all PCI cases. The number of DES, both per
patient and per lesion, was equally distributed among
groups, with 1.31 stents/patient and 1.18 stents/lesion in
the normal-weight subset, 1.33 stents/patient and 1.18
stents/lesion with overweight, and 1.33 stents/patient and
1.21 stents/lesion in obese patients, respectively. The diam-
eter of stents used in obese patients was larger than that used
for patients in the overweight and normal weight groups
(Table 3).
In-hospital follow-up. The overall in-hospital MACCE rate
as 2.4% in the normal weight, 2.2% in the overweight, and
.6% in the obese groups (p  0.10). Similarly, rates for MI
DES
BMI, kg/m2
p Trend25–30 >30
3,197 1,685 0.05
3,771 2,042 0.05
87.2 10.7 86.8 10.8 0.29
3.0 (2.5–3.0) 3.0 (2.8–3.0) 0.001
18.0 (13.0–24.0) 18.0 (13.0–24.0) 0.09
0.7 0.6 0.73
0.5 0.5 0.49
0.3 0.3 0.31
40.8 41.8 0.71
1.8 7.0 1.9 8.0 0.63
97.8 98.4 0.92
0.1 0.3 0.65
0.2 0.4 0.56
0.2 0.1 0.36
36.4 36.9 0.34
48.9 49.2 0.29
17.1 16.6 0.67ivingin Tables 1 and 2.
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166and stroke, as well as for severe bleeding complications, were
always low, with no differences between subsets. Conversely,
in-hospital death rate trended slightly higher, with normal
weight in 0.8% versus 0.5% and 0.3% (p  0.05) (Table 4).
ntithrombotic medication at discharge was similar, with
ual antiplatelet therapy in over 99%, and combined dual
ntithrombotic and anticoagulation therapy in 2.7%.
1-year follow-up. Complete clinical outcomes after a mean
follow-up of 12.4 months were available in 97.1% of
Table 4. In-Hospital and 1-Year Clinical Follow-Up of Patients
Receiving DES
BMI, kg/m2
p Trend18.5–24.9 25–30 >30
In-hospital follow-up
Death 0.8 0.5 0.3 0.05
Myocardial infarction 1.4 1.3 1.0 0.39
Stroke 0.4 0.7 0.3 0.52
MACCE 2.4 2.2 1.6 0.10
Repeat urgent
revascularization
PCI 1.0 0.8 0.7 0.44
CABG 0 0.1 0.3 0.05
Repeat elective
revascularization
PCI 2.3 2.2 3.9 0.81
CABG 0.7 0.5 1.6 0.31
Transient renal failure
requiring single dialysis
1.8 1.7 1.0 0.08
Severe bleeding
complications
0.6 0.5 0.7 0.74
Hospitalization 3 days 33.7 31.3 32.4 0.47
Triple antiplatelet therapy 2.3 3.4 1.8 0.32
1-year follow-up
Clinical follow-up 96.6 97.2 97.3 0.28
Death 3.3 2.4 2.4 0.17
Myocardial infarction 2.8 2.3 2.3 0.45
Stroke 1.2 1.1 0.9 0.32
MACCE 7.1 5.6 5.5 0.09
TVR 10.9 11.7 11.6 0.56
Overall ST according ARC 4.7 4.0 4.0 0.35
Deﬁnite 1.2 1.2 1.1 0.93
Probable 1.1 0.8 0.6 0.26
Possible 2.4 2.0 2.3 0.41
ASA 94.7 93.8 91.2 0.24
Clopidogrel 57.9 53.1 57.0 0.53
Oral anticoagulation 7.5 8.7 12.9 0.20
Bleeding
Major 2.5 2.1 2.8 0.53
Minor 57.2 46.3 45.7 0.0011
Values are %.
ARC  Academic Research Consortium; ASA  acetylsalicylic acid; CABG  coronary bypass
graft; MACCE  major adverse cardiac and cerebrovascular event; ST  stent thrombosis;
TVR target vessel revascularization; other abbreviations as in Table 1.patients (Table 4); in 2.9%, the 1-year outcomes were notcompleted. No significant differences were noted between
groups with respect to the incidence of MACCE-free
survival and TVR-free survival (Figs 1 and 2). Similarly, no
differences were noted in the rates of MI, stroke, and
definite stent thrombosis (Table 4). Yet, compared with the
obese and overweight groups, patients with normal weight
had significantly higher rates of minor bleeding (57.2%
versus 46.3% and 45.7%; p  0.001) although antiplatelet
therapy was similar. Subgroup analysis between outcomes
after using SES or PES revealed no differences between
both DES for primary endpoints MACCE and TVR,
Figure 1. MACCE-Free Survival
1-year major adverse cardiac and cerebrovascular events (MACCE)-free sur-
vival in normal weight, overweight, and obese patients treated with drug-
eluting stents. BMI  body mass index; PCI  percutaneous coronary
intervention.
Figure 2. TVR-Free Survival
1-year target vessel revascularization (TVR)-free survival in normal weight,
overweight, and obese patients treated with drug-eluting stents. Abbrevia-
tions as in Figure 1.
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167regardless of the BMI. With minor differences in baseline
characteristics, subsequent multivariable analysis revealed no
impact of overweight and obesity on primary endpoints at 1
year. After risk adjustment, rates for both MACCE and
TVR remained similar between groups (Figs. 3 and 4).
iscussion
With growing recognition that obesity adversely influences
traditional cardiovascular risk factors, such as hypertension,
elevated plasma lipids, diabetes mellitus and metabolic
syndrome, the American Heart Association defines obesity
as a strong predictor for coronary artery disease (15).
Increasing insulin resistance, enhanced free fatty acid turn-
over, elevated basal sympathetic tone, hypercoagulable
blood, and promotion of systemic inflammation are patho-
Figure 3. Predictors for MACCE
Predictors for MACCE in the overall patient population. CABG  coronary arte
infarction; other abbreviations as in Figure 1.
Figure 4. Predictors for TVRPredictors for TVR in the overall patient population. OR  odds ratio; other abbreviaphysiological changes by which obesity promotes the risk for
coronary artery disease (16). Although obesity has tradition-
ally been identified as independent marker for coronary
events, recent studies have described an “obesity paradox” in
patients undergoing PCI or CABG, reporting similar or
lower post-operative mortality in obese patients compared
with patients with normal weight (3–7). This so-called
paradox has even been extended to conditions such as ACS
and heart failure (17,18). Gruberg et al. (5) categorized
9,633 consecutive patients undergoing PCI in groups with
BMI 24.9 kg/m2 (n  1,923), BMI  25 to 30 kg/m2
(n  4,813), and BMI 30 kg/m2 (n  2,897); despite
imilar angiographic success rates, normal BMI patients had
higher incidence of major in-hospital complications,
ncluding cardiac death (1.0% vs. 0.7% vs. 0.4%; p  0.001)
ass graft; HR  hazard ratio; STEMI  ST-segment elevation myocardialry byptions as in Figures 1 and 3.
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168than overweight and obese patients. At 1 year, mortality was
significantly higher in normal BMI patients compared with
overweight or obese patients, both for overall (10.6% vs.
5.7% vs. 4.9%; p  0.0001) and for cardiac mortality (4.8%
s. 3.3% vs. 2.5%; p  0.0001), whereas rates of myocardial
nfarction and revascularization were similar despite a better
aseline clinical profile with normal weight. A meta-
nalysis, including 250,152 patients with coronary artery
isease and a mean follow-up of 3.8 years, suggested similar
bservations with a low BMI (20 kg/m2) associated with
an increased relative risk (RR) for overall mortality (RR:
1.37 [95% confidence interval (CI): 1.32 to 1.43]), and
cardiovascular mortality (RR: 1.45 [95% CI: 1.16 to 1.81]),
whereas overweight patients (BMI: 25 to 29.9 kg/m2)
enjoyed a low risk for both overall (RR: 0.87 [95% CI: 0.81
to 0.94] and cardiac mortality (RR: 0.88 [95% CI: 0.75 to
1.02]) (19). Such findings were mirrored in registries with
BMI of 27.5 to 30 kg/m2 leading to reduced risk of dying
at 5 years (hazard ratio: 0.59, 95% CI: 0.39 to 0.90; p 
0.014) (20), underlining a protective notion of obesity.
Other trials not supporting any protective notion of
obesity are in fact corroborated by randomized data from
TAXUS-IV (TAXUS IV-SR: Treatment of De Novo
Coronary Disease Using a Single Paclitaxel-Eluting
Stent) where overweight (BMI: 25 to 30 kg/m2) and
bese (BMI 30 kg/m2) patients revealed higher
-month restenosis rates (29.2% and 30.5%) than pa-
ients with normal weight (9.3%; p  0.01) and higher
ACE rates (20.8% and 23.2% vs. 11.1%; p  0.02)
ith BMS, whereas no differences in restenosis and
ACE with PES were noted at 1 year (21). Similar
ndings were reported in ARTS II (Arterial Revascular-
zation Therapies Study II) trial, with similar rates for
ACE after receiving SES regardless of obesity (22).
Results from DES.DE are unique, considering the im-
act of BMI on clinical outcomes after DES implantation in
outine clinical practice. Compared with overweight and
bese patients, those with normal body weight had similar
ates of all-cause mortality and MACCE as well as TVR,
I, stroke, and stent thrombosis even after risk adjustment.
lthough our data challenge the so-called obesity paradox,
he concept may actually be a misnomer, or may in fact not
xist at all. Overweight and obese patients are usually
ounger, with larger culprit vessel diameter than normal
eight counterparts; their comorbidity index is usually
igher without any differences in the extent of coronary
rtery disease. Moreover, it is well established that younger
atients have better clinical outcomes after acute MI regard-
ess of reperfusion modality (23,24). Additionally, the pres-
nce of comorbidities in obese and overweight patients
sually led to more aggressive therapy of cardiovascular risk
actors likely to improve outcomes despite obesity (23,24).
he relationship of obesity to long-term survival is complex,
robably characterized by a J- or U-shaped curve, withncreasing mortality in the very lean or severely obese group
25,26); however, when adjusted for smoking and concur-
ent illness, the relationship has always been linear
2,27,28). A low BMI may in fact be a marker of severe
ystemic illness, since low BMI is associated with a higher
ate of noncardiac mortality (2,29). By defining the normal-
eight group from 18.5 to 24.9 kg/m2, 16 extremely
underweight patients were excluded because they were
suffering from severe systemic illness. If patients with a BMI
18.5 kg/m2 were to be included, a significant difference in
MACCE-free survival would emerge between groups (p 
0.04); a BMI of 25 kg/m2 (including the extremely
underweight patients) would be associated with a
MACCE-free survival of 90.2%, a BMI between 25 and 30
kg/m2 with 92%, and a BMI of 30 kg/m2 with 92.7%
ACCE-free survival, respectively. No difference would be
een in TVR-free survival between groups (83.3% vs. 83.2%
s. 83.7%; p  0.91).
Several prospective investigations have recently shown
hat subjects with BMI 25 kg/m2 were more likely to
uffer from suboptimal platelet response to clopidogrel and
spirin treatment (30,31). Again, such findings could not be
onfirmed in the real-world setting of DES.DE, with
imilar rates of stent thrombosis in all subsets.
Study limitations. The present study suffers from the
nherent limitation of an observational study. Potentially
onfounding variables such as physical inactivity, unin-
ended weight loss, and socioeconomic factors were not
nalyzed, but may have influenced the results. Both
everity of obesity were estimated by using the BMI as a
omentum without any information on weight change.
part from weight, both waist circumference and waist-
o-hip ratio were unavailable; such alternative criteria for
besity may be more closely related to cardiovascular
isease and death than BMI. Eventually any potential
elation between obesity and survival may be lost the
onger patients are followed. Yet, with extended follow-
p, cumulative detrimental effect of obesity may even
anifest as increased late mortality.
onclusions
Data from DES.DE revealed no evidence of the “obesity
paradox” in patients subjected to DES treatment in routine
clinical practice with mortality, MI, stroke, stent thrombo-
sis, MACCE, and TVR rates being independent of both
BMI and choice of PES or SES. Prospective studies with
long-term follow-up designed to confirm or refute the
obesity paradox in the context of DES are required, focusing
on fat distribution, central adiposity, temporal weight loss,
and weight change.
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